Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Bupropion in the Treatment of Pathological Gambling

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00055393
Recruitment Status : Completed
First Posted : March 3, 2003
Last Update Posted : March 14, 2017
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
Donald Black, University of Iowa

Brief Summary:
This study will determine whether the drug bupropion is an effective treatment for Pathological Gambling.

Condition or disease Intervention/treatment Phase
Pathological Gambling Drug: Bupropion Drug: Placebo Not Applicable

Detailed Description:

As gambling opportunities proliferate, PG has become a major health concern. Despite its importance, few treatment options with proven efficacy exist. This study will attempt to identify an effective treatment for PG.

Participants are randomly assigned to receive either bupropion or placebo for 12 weeks. Participants are assessed at baseline and at Weeks 2, 3, 4, 5, 6, 8, 10, and 12. Self administered questionnaires and interviews are used to assess participants. Follow-up assessments are made 1, 3, and 6 months after study completion.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Bupropion Versus Placebo in the Treatment of Pathological Gambling
Study Start Date : July 2002
Actual Primary Completion Date : May 2005
Actual Study Completion Date : April 2006

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Subjects receivng Bupropion
The active arm subjects in this study (n = 18) received flexibly dosed bupropion in this randomized 12-week double-blind trial.
Drug: Bupropion
18 subjects in this randomly controlled double blind study received bupropion.

Placebo Comparator: Subjects receiving Placebo
The inactive arm subjects in this randomly controlled study (n = 21) received a placebo.
Drug: Placebo
21 subjects received Placebo.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Meet the criteria for Pathological Gambling (DSM-IV-TR), through the administration of the National Opinion Research Center DSM Screen for Gambling Problems(NODS);
  • Meet the criteria for Pathological Gambling (DSM-IV-TR), through the administration of the National Opinion Research Center DSM Screen for Gambling Problems(NODS);
  • Receive a score of 5 or more on the South Oaks Gambling Screen (SOGS);
  • Have PG for at least one year;
  • Have had at least 2 or more gambling episodes during the 2-week screening period;
  • Speak standard English;
  • Be able to give written informed consent.

Exclusion Criteria:

  • Evidence of current (past 3 months) substance misuse;
  • Had a Hamilton Depression Rating Scale (HDRS)27 score of 18 or more (or a score on item 1 of greater than 2;
  • Had a current eating disorder (except binge eating disorder);
  • Had any history of seizures, or suicidal or aggressive behavior;
  • Had a urine drug screen positive for stimulants, opiates, hallucinogens, or phencyclidine;
  • Had a current or past psychotic disorder, bipolar disorder, or significant cognitive disorder;
  • Received monoamine oxidase inhibitors within 3 weeks of randomization, long acting phenothiazine within 3 months of randomization,fluoxetine within 4 weeks of randomization, or other psychotropic drugs within 2 weeks of randomization;
  • Had prior exposure to bupropion;
  • Were engaged in individual, group, or couples psychotherapy during the 2 weeks before randomization, (except Gamblers Anonymous).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00055393

Layout table for location information
United States, Iowa
Roy J. and Lucille A. Carver College of Medicine, University of Iowa
Iowa City, Iowa, United States, 52242
Sponsors and Collaborators
University of Iowa
National Institute of Mental Health (NIMH)
Layout table for investigator information
Principal Investigator: Donald W Black, MD University of Iowa

Publications of Results:
Layout table for additonal information
Responsible Party: Donald Black, Professor of and MD in Psychiatry, University of Iowa Identifier: NCT00055393    
Other Study ID Numbers: 200007038
R21MH063289 ( U.S. NIH Grant/Contract )
First Posted: March 3, 2003    Key Record Dates
Last Update Posted: March 14, 2017
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: There is no plan to share individual participant data.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Disruptive, Impulse Control, and Conduct Disorders
Mental Disorders
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors